Pro Medicus has the GF Score of 99, which implies that the company
might have
Highest outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Pro Medicus
might have
Highest outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Pro Medicus (ASX:PME) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Pro Medicus GF Score Related Terms
ASX:PME vs VEEV, BTSG, TEM: GF Score Comparison
For the Health Information Services subindustry, Pro Medicus's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro Medicus GF Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pro Medicus's GF Score distribution charts can be found below:
* The bar in red indicates where Pro Medicus's GF Score falls into.
Pro Medicus (ASX:PME) has a GF Score of 99 as of Jul. 02, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Pro Medicus and its competitors. This is 14% above median its historical median of 87.00. Over the past decade, Pro Medicus' GF Score has ranged from 63.00 to 99.00.
Is Pro Medicus' GF Score too high?
Pro Medicus' current GF Score of 99 is 14% above median its 10-year median of 87.00. Over the past 10 years, this metric has ranged from a low of 63.00 to a high of 99.00. Overall, Pro Medicus has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pro Medicus' GF Score compare to VEEV and BTSG?
Pro Medicus' GF Score of 99 can be compared against companies in the Healthcare Providers & Services industry. Historically, Pro Medicus' own GF Score has ranged from 63.00 to 99.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Healthcare Providers & Services company?
A good GF Score depends on the Healthcare Providers & Services industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Pro Medicus and its competitors. Pro Medicus's current GF Score is 99, which is 14% above median its own 10-year median of 87.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro Medicus stock overvalued right now?
Based on GuruFocus' analysis, Pro Medicus (ASX:PME) is currently considered Modestly Undervalued. The stock's GF Value™ is A$245.90, compared to a current price of A$205.93 — trading 16.3% below its estimated fair value. The current GF Score is 99, which is 14% above median its 10-year median of 87.00. Pro Medicus' overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Pro Medicus (ASX:PME), the current GF Score is 99 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro Medicus (ASX:PME) Overvalued in 2026?
Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued.
The current stock price of A$205.93 is trading 16.3% below its estimated GF Value™ of A$245.90.
GuruFocus considers Pro Medicus to be Modestly Undervalued.
Key valuation signals for ASX:PME:
GF Score: 99 (14% above median its 10-year median of 87.00)
GF Value™: A$245.90 vs. price of A$205.93 (16.3% below fair value)
No single metric tells the full story. See the ASX:PME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
99GF Score
Get the complete analysis for ASX:PME
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PME has been successfully added to your 